Infinium Pharmachem Ltd
Infinium Pharmachem Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Infinium Pharmachem Ltd Q2 FY27 key numbers
- Revenue
- Year-on-year increase in standalone revenue: Approximately Rs. 3,940.98 Lacs (about 54.3% increase).
As stated in Infinium Pharmachem Ltd's Q2 FY27 results statement · published 7 Nov 2026. Reported figures, not investment advice.
Based on Infinium Pharmachem Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from Operations (Standalone) for the half year ended September 30, 2026: Rs. 11,201.35 Lacs. EBITDA for the quarter: Rs. 1,129 million, up 17% YoY.
From Infinium Pharmachem Ltd's Q2 FY27 earnings-call transcript · updated 7 Nov 2026.
How did Infinium Pharmachem's revenue grow in the September 2026 quarter?
- Revenue from Operations (Standalone) for the half year ended September 30, 2026: Rs. 11,201.35 Lacs
- Revenue from Operations (Standalone) for the half year ended September 30, 2025: Rs. 7,260.37 Lacs
- Year-on-year increase in standalone revenue: Approximately Rs. 3,940.98 Lacs (about 54.3% increase)
- Consolidated net profit before tax for half year ended September 30, 2026: Rs. 1,300.89 Lacs (vs Rs. 833.03 Lacs in 2025)
What happened to Infinium Pharmachem's margins in Q2 FY27?
See what Infinium Pharmachem Ltd said on profitability & margins — free account, 30 seconds.
What capex is Infinium Pharmachem planning?
See what Infinium Pharmachem Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Infinium Pharmachem raising money or cutting debt?
See what Infinium Pharmachem Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Infinium Pharmachem's order book?
See what Infinium Pharmachem Ltd said on order book & pipeline — free account, 30 seconds.
Continue your research
What Infinium Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Divis Laboratories (Q2 FY27)
Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec
- Walpar Nutrition (Q2 FY27)
3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- NGL Fine Chem (Q2 FY27)
Consolidated: ₹15,870.73 lakhs . Key results statement takeaways from NGL Fine Chem Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Infinium Pharmachem Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Infinium Pharmachem Ltd Q2 FY27 results?
Revenue from Operations (Standalone) for the half year ended September 30, 2026: Rs. 11,201.35 Lacs. EBITDA for the quarter: Rs. 1,129 million, up 17% YoY.
What is Infinium Pharmachem Ltd share price analysis?
Infinium Pharmachem Ltd currently shows a neutral. The stock trades at a P/E of 35.8 with a market cap of ₹435 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Infinium Pharmachem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.